Media headlines about Maximus (NYSE:MMS) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Maximus earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned media stories about the health services provider an impact score of 72 out of 100, meaning that recent news coverage is likely to have an effect on the company’s share price in the near future.

Insider Buying and Selling by Quarter for Maximus (NYSE:MMS)

MMS has been the topic of several research reports. Canaccord Genuity restated a “buy” rating and set a $62.00 price target on shares of Maximus in a research note on Friday, April 7th. ValuEngine lowered Maximus from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Jefferies Group LLC lowered Maximus from a “buy” rating to a “hold” rating and boosted their price target for the company from $63.00 to $64.00 in a research note on Friday, May 5th. Maxim Group lowered Maximus from a “buy” rating to a “hold” rating and set a $66.00 price target on the stock. in a research note on Thursday, May 4th. They noted that the move was a valuation call. Finally, KeyCorp restated a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $61.33.

Maximus (NYSE:MMS) traded down 0.41% during midday trading on Wednesday, hitting $63.27. The stock had a trading volume of 76,012 shares. Maximus has a 1-year low of $43.69 and a 1-year high of $64.97. The company has a market cap of $4.10 billion, a price-to-earnings ratio of 20.74 and a beta of 1.45. The company’s 50 day moving average is $62.93 and its 200 day moving average is $59.50.

Maximus (NYSE:MMS) last released its quarterly earnings results on Thursday, May 4th. The health services provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Maximus had a net margin of 8.18% and a return on equity of 26.21%. The company had revenue of $622 million during the quarter, compared to the consensus estimate of $620.24 million. During the same period in the previous year, the business earned $0.74 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. On average, equities analysts anticipate that Maximus will post $3.05 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 31st. Stockholders of record on Monday, May 15th were given a $0.045 dividend. The ex-dividend date of this dividend was Thursday, May 11th. This represents a $0.18 dividend on an annualized basis and a dividend yield of 0.28%. Maximus’s payout ratio is 5.86%.

In other news, CEO Richard A. Montoni sold 30,000 shares of Maximus stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $62.81, for a total value of $1,884,300.00. Following the completion of the sale, the chief executive officer now directly owns 584,114 shares in the company, valued at $36,688,200.34. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Russell A. Beliveau sold 1,500 shares of Maximus stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $63.82, for a total transaction of $95,730.00. Following the completion of the sale, the director now owns 41,829 shares of the company’s stock, valued at $2,669,526.78. The disclosure for this sale can be found here. Over the last quarter, insiders sold 120,846 shares of company stock valued at $7,582,041. 3.10% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Financial Market News and is the sole property of of Financial Market News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at

Maximus Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with's FREE daily email newsletter.